对骨髓标本细胞质空泡化进行靶向检测以识别既往未诊断的VEXAS综合征病例
该研究回顾性筛查2014年5月1日至2022年2月18日骨髓报告中细胞质空泡化的男性患者,用5分量表评估VEXAS综合征怀疑度,对中度或高度怀疑且有DNA材料者检测体细胞UBA1变异;8例检测者中7例(87.5%)检出致病性体细胞UBA1变异。
要点
- 骨髓细胞质空泡化患者中,5分量表评出中度至高度怀疑者21例。
- 有DNA材料且中度或高度怀疑的8例中,7例(87.5%)检出致病性体细胞UBA1变异。
- VEXAS综合征患者骨髓空泡化分布:红系与髓系前体6/7,仅红系前体1/7,仅髓系前体0/7。
核心结论
- 在此研究中,采用临床可操作的靶向筛查方法检测骨髓标本(伴空泡化)中既往未诊断的VEXAS综合征,阳性检出率为87.5%。
研究设计与样本
- 回顾性研究,审查2014年5月1日至2022年2月18日骨髓报告中细胞质空泡化的男性患者。
- 排除急性白血病、淋巴瘤、转移性实体瘤、淀粉样变性或POEMS综合征患者,以及无临床记录可供直接病历审查者。
- 用基于实验室发现、临床特征和治疗反应的5分量表评估VEXAS综合征怀疑度。
- 对有DNA材料且中度(3分)或高度(4至5分)怀疑的患者检测与VEXAS综合征相关的体细胞UBA1变异。
主要发现
- 292例独特患者的315份报告记录了空泡化。
- 按排除标准筛选后,64例患者接受直接病历审查以评估VEXAS综合征可能性,其中21例达到中度至高度怀疑。
- 8例有可用DNA,其中7例(87.5%)携带与VEXAS综合征一致的致病性体细胞UBA1变异。
- VEXAS综合征患者骨髓活检报告中细胞质空泡化分布为红系和髓系前体(6/7)、仅红系前体(1/7)、仅髓系前体(0/7)。
关键数值与推荐
- VEXAS综合征怀疑度采用5分量表,中度怀疑为3分,高度怀疑为4至5分。
- 靶向筛查阳性检出率为87.5%(7/8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To retrospectively identify patients with VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic syndrome) among male patients with bone marrow vacuolization using a clinically applicable, targeted-screening approach. METHODS: Bone marrow reports from 1 May 2014 through 18 February 2022 were reviewed for documentation of cytoplasmic vacuolization. Patients with acute leukaemia, lymphoma, metastatic solid tumour, amyloidosis or POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome were excluded, as were those without clinical records available for direct chart review. Cases were rated for suspicion of VEXAS syndrome using a 5-point scale based on the presence of laboratory findings, clinical features and treatment response. Patients with available DNA material and moderate (three patients) or high (four to five patients) suspicion were tested for somatic UBA1 variants associated with VEXAS syndrome. RESULTS: A total of 315 reports from 292 unique patients included documentation of vacuolization. Following exclusion criteria, 64 patients underwent direct medical chart review to assess likelihood of VEXAS syndrome, for which 21 patients met moderate to high suspicion. Available DNA was present in eight patients, seven (87.5%) of whom had a pathogenic somatic UBA1 variant consistent with VEXAS syndrome. The distribution of cytoplasmic vacuolization in the bone marrow biopsy reports among patients with VEXAS syndrome were erythroid and myeloid precursors (6/7), erythroid precursors only (1/7) and myeloid precursors only (0/7). CONCLUSION: In this study, the utilization of a clinically applicable targeted-screening approach to test bone marrow specimens (with vacuolization) for the presence of previously undiagnosed VEXAS syndrome resulted in a positive detection rate of 87.5%.
引用
- Hines AS, Koster MJ, Bock AR, et al. Targeted testing of bone marrow specimens with cytoplasmic vacuolization to identify previously undiagnosed cases of VEXAS syndrome. Rheumatology (Oxford). 2023. PMID: 37228016. doi:10.1093/rheumatology/kead245
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。